Targeting tumor microenvironment: Crossing tumor interstitial fluid by multifunctional nanomedicines

BioImpacts

Volumn 4, Issue 2, 2014, Pages 55-67

  Omidi, Yadollah ^a   Barar, Jaleh ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Nanomedicines; Targeted therapy of cancer; Theranostics; Tumor interstitium; Tumor microcirculation; Tumor microenvironment

Indexed keywords

DEXAMETHASONE; MAGNETIC NANOPARTICLE; NANOPARTICLE; NICOTINAMIDE; PLATELET DERIVED GROWTH FACTOR; VASCULOTROPIN;

BLOOD FLOW; CANCER CELL; CANCER CHEMOTHERAPY; CARCINOGENESIS; CELL METABOLISM; DRUG DELIVERY SYSTEM; ENERGY METABOLISM; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; HUMAN; HYPERTHERMIC THERAPY; IMMUNOSURVEILLANCE; INTERSTITIAL FLUID; MICROVASCULATURE; NANOMEDICINE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PROTEIN TARGETING; REVIEW; SOLID TUMOR; STROMA CELL; TISSUE PRESSURE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; VASCULAR RESISTANCE; WATER TRANSPORT;

EID: 84905435584     PISSN: 22285652     EISSN: 22285660     Source Type: Journal    
DOI: 10.5681/bi.2014.021     Document Type: Review

References (119)

1. Barar J, Omidi Y. Dysregulated pH in tumor microenvironment checkmates cancer therapy modalities. Bioimpacts 2013; 3: 149-62.
2. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 2004; 4: 806-13.
3. Gromov P, Gromova I, Olsen CJ, Timmermans-Wielenga V, Talman ML, Serizawa RR, et al. Tumor interstitial fluid - a treasure trove of cancer biomarkers. Biochim Biophys Acta 2013; 1834: 2259-70.
4. Omidi Y, Gumbleton M. Biological Membranes and Barriers. In: Mahato RI, editor. Biomaterials for Delivery and Targeting of Proteins Nucleic Acids. New York: CRC Press; 2005. p. 232-74.
5. Matzinger P. Friendly and dangerous signals: is the tissue in control? Nat Immunol 2007; 8: 11-3.
6. Gray SG, Eriksson T, Ekstrom TJ. Methylation, gene expression and the chromatin connection in cancer (review). Int J Mol Med 1999; 4: 333-50.
7. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
8. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004; 4: 891-9.
9. Martinez-Outschoorn UE, Balliet RM, Lin Z, Whitaker-Menezes D, Howell A, Sotgia F, et al. Hereditary ovarian cancer and two-compartment tumor metabolism: Epithelial loss of BRCA1 induces hydrogen peroxide production, driving oxidative stress and NFkappaB activation in the tumor stroma. Cell Cycle 2012; 11: 4152-66.
10. Maes H, Rubio N, Garg AD, Agostinis P. Autophagy: shaping the tumor microenvironment and therapeutic response. Trends Mol Med 2013; 19: 428-46.
11. Xu Y, Xia X, Pan H. Active autophagy in the tumor microenvironment: A novel mechanism for cancermetastasis. Oncol Lett 2013; 5: 411-6.
12. Salem AF, Whitaker-Menezes D, Lin Z, Martinez-Outschoorn UE, Tanowitz HB, Al-Zoubi MS, et al. Two compartment tumor metabolism: autophagy in the tumor microenvironment and oxidative mitochondrial metabolism (OXPHOS) in cancer cells. Cell Cycle 2012; 11: 2545-56.
13. Martinez-Outschoorn UE, Pavlides S, Howell A, Pestell RG, Tanowitz HB, Sotgia F, et al. Stromal-epithelial metabolic coupling in cancer: integrating autophagy and metabolism in the tumor microenvironment. Int J Biochem Cell Biol 2011; 43: 1045-51.
14. Martinez-Outschoorn UE, Lin Z, Trimmer C, Flomenberg N, Wang C, Pavlides S, et al. Cancer cells metabolically "fertilize" the tumor microenvironment with hydrogen peroxide, driving the Warburg effect: implications for PET imaging of human tumors. Cell Cycle 2011; 10: 2504-20.
15. Barar J, Omidi Y. Dysregulated pH in Tumor Microenvironment Checkmates Cancer Therapy. Bioimpacts 2013; 3: 149-62.
16. Reshkin SJ, Cardone RA, Harguindey S. Na+-H+ exchanger, pH regulation and cancer. Recent Pat Anticancer Drug Discov 2013; 8: 85-99.
17. Barar J. Targeting tumor microenvironment: the key role of immune system. Bioimpacts 2012; 2: 1-3.
18. Stockmann C, Schadendorf D, Klose R, Helfrich I. The Impact of the Immune System on Tumor: Angiogenesis and Vascular Remodeling. Front Oncol 2014; 4: 69.
19. Friday E, Oliver R, Welbourne T, Turturro F. Glutaminolysis and glycolysis regulation by troglitazone in breast cancer cells: Relationship to mitochondrial membrane potential. J Cell Physiol 2011; 226: 511-9.
20. Wong P, Lee C, Tannock IF. Reduction of intracellular pH as a strategy to enhance the pH-dependent cytotoxic effects of melphalan for human breast cancer cells. Clin Cancer Res 2005; 11: 3553-7.
21. Steffan JJ, Snider JL, Skalli O, Welbourne T, Cardelli JA. Na+/H+ exchangers and RhoA regulate acidic extracellular pH-induced lysosome trafficking in prostate cancer cells. Traffic 2009; 10: 737-53.
22. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-32.
23. Nyberg P, Salo T, Kalluri R. Tumor microenvironment and angiogenesis. Front Biosci 2008; 13: 6537-53.
24. Jain RK. Transport of molecules across tumor vasculature. Cancer Metastasis Rev 1987; 6: 559-93.
25. Jain RK. Determinants of tumor blood flow: a review. Cancer Res 1988; 48: 2641-58.
26. Furuya M, Nishiyama M, Kasuya Y, Kimura S, Ishikura H. Pathophysiology of tumor neovascularization. Vasc Health Risk Manag 2005; 1: 277-90.
27. Furuya M, Yonemitsu Y, Aoki I. III. Angiogenesis: complexity of tumor vasculature and microenvironment. Curr Pharm Des 2009; 15: 1854-67.
28. Adiseshaiah PP, Hall JB, McNeil SE. Nanomaterial standards for efficacy and toxicity assessment. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010; 2: 99-112.
29. Catalano V, Turdo A, Di Franco S, Dieli F, Todaro M, Stassi G. Tumor and its microenvironment: a synergistic interplay. Semin Cancer Biol 2013; 23: 522-32.
30. Chung AS, Ferrara N. Targeting the tumor microenvironment with SRC kinase inhibition. Clin Cancer Res 2010; 16: 775-7.
31. Liang W, Kujawski M, Wu J, Lu J, Herrmann A, Loera S, et al. Antitumor activity of targeting SRC kinases in endothelial and myeloid cell compartments of the tumor microenvironment. Clin Cancer Res 2010; 16: 924-35.
32. Martinez-Outschoorn UE, Curry JM, Ko YH, Lin Z, Tuluc M, Cognetti D, et al. Oncogenes and inflammation rewire host energy metabolism in the tumor microenvironment: RAS and NFkappaB target stromal MCT4. Cell Cycle 2013; 12: 2580-97.
33. Seguin L, Weis SM, Cheresh DA. Variety in the tumor microenvironment: integrin splicing regulates stemness. Cell Stem Cell 2014; 14: 557-8.
34. Macheda ML, Stacker SA. Importance of Wnt signaling in the tumor stroma microenvironment. Curr Cancer Drug Targets 2008; 8: 454-65.
35. Bailey JM, Leach SD. Signaling pathways mediating epithelial- mesenchymal crosstalk in pancreatic cancer: Hedgehog, Notch and TGFbeta. In: Grippo PJ, HG Munshi, editors. Pancreatic Cancer and Tumor Microenvironment. Trivandrum (India)2012.
36. Li SP, Padhani AR. Tumor response assessments with diffusion and perfusion MRI. J Magn Reson Imaging 2012; 35: 745-63.
37. Jordan BF, Sonveaux P. Targeting tumor perfusion and oxygenation to improve the outcome of anticancer therapy. Front Pharmacol 2012; 3: 94.
38. Matsuo M, Matsumoto S, Mitchell JB, Krishna MC, Camphausen K. Magnetic Resonance Imaging of the Tumor Microenvironment in Radiotherapy: Perfusion, Hypoxia, and Metabolism. Semin Radiat Oncol 2014; 24: 210-7.
39. Gee MS, Saunders HM, Lee JC, Sanzo JF, Jenkins WT, Evans SM, et al. Doppler ultrasound imaging detects changes in tumor perfusion during antivascular therapy associated with vascular anatomic alterations. Cancer Res 2001; 61: 2974-82.
40. Ta CN, Kono Y, Barback CV, Mattrey RF, Kummel AC. Automating tumor classification with pixel-by-pixel contrast-enhanced ultrasound perfusion kinetics. J Vac Sci Technol B Nanotechnol Microelectron 2012; 30: 2C103.
41. de Langen AJ, Lubberink M, Boellaard R, Spreeuwenberg MD, Smit EF, Hoekstra OS, et al. Reproducibility of tumor perfusion measurements using 15O-labeled water and PET. J Nucl Med 2008; 49: 1763-8.
42. Mertens J, Ham H, De Zutter A, Depicker A, Van de Wiele C, Smeets P, et al. Tumor perfusion using first-pass F-18 FDG PET images. Clin Nucl Med 2012; 37: 166-7.
43. Apostolova I, Hofheinz F, Buchert R, Steffen IG, Michel R, Rosner C, et al. Combined measurement of tumor perfusion and glucose metabolism for improved tumor characterization in advanced cervical carcinoma. A PET/CT pilot study using [15O]water and [18F]fluorodeoxyglucose. Strahlenther Onkol 2014; 190: 575-81.
44. Hermans R, Van den Bogaert W. Outcome prediction after surgery and chemoradiation of head-and-neck squamous cell carcinoma (HNSCC), using baseline perfusion computed tomography (CT) microcirculatory parameters vs. tumor volume. Int J Radiat Oncol Biol Phys 2009; 74: 1307; author reply
45. Petralia G, Preda L, Giugliano G, Jereczek-Fossa BA, Rocca A, D'Andrea G, et al. Perfusion computed tomography for monitoring induction chemotherapy in patients with squamous cell carcinoma of the upper aerodigestive tract: correlation between changes in tumor perfusion and tumor volume. J Comput Assist Tomogr 2009; 33: 552-9.
46. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001; 41: 189-207.
47. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhancedpermeability and retention effect for tumor targeting. Drug Discov Today 2006; 11: 812-8.
48. Flessner MF, Choi J, Credit K, Deverkadra R, Henderson K. Resistance of tumor interstitial pressure to the penetration of intraperitoneally delivered antibodies into metastatic ovarian tumors. Clin Cancer Res 2005; 11: 3117-25.
49. Wu M, Frieboes HB, Chaplain MA, McDougall SR, Cristini V, Lowengrub JS. The effect of interstitial pressure on therapeutic agent transport: Coupling with the tumor blood and lymphatic vascular systems. J Theor Biol 2014; 355: 194-207.
50. Jain RK. Transport of macromolecules in tumor microcirculation. Biotechnol Prog 1985; 1: 81-94.
51. Jain RK. Transvascular and interstitial transport in tumors. Adv Exp Med Biol 1988; 242: 215-20.
52. Baish JW, Netti PA, Jain RK. Transmural coupling of fluid flow in microcirculatory network and interstitium in tumors. Microvasc Res 1997; 53: 128-41.
53. Shieh AC, Swartz MA. Regulation of tumor invasion by interstitial fluid flow. Phys Biol 2011; 8: 015012.
54. Wiig H, Swartz MA. Interstitial fluid and lymph formation and transport: physiological regulation and roles in inflammation and cancer. Physiol Rev 2012; 92: 1005-60.
55. Fahraus R, Lindqvist T. The viscosity of the blood in narrow capillary tubes. American Journal of Physiology 1931; 96: 562-8.
56. Baronzio G, Freitas I, Hau K. Significance of Tumor Microenvironment on the Genesis of: Interstitial Fluid, Angiogenesis, Haemostatic/Haemorheologic Abnormalities. Pathogenesis and Therapeutic Aspects. In: Baronzio G, CR Cogle, editors. Cancer Microenvironment and Therapeutic Implications: Tumor Pathophysiology Mechanisms and Therapeutic Strategies. New York: Springer; 2009.
57. Starling EH. On the Absorption of Fluids from the Connective Tissue Spaces. J Physiol 1896; 19: 312-26.
58. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res 1987; 47: 3039-51.
59. McDonald DM, Foss AJ. Endothelial cells of tumor vessels: abnormal but not absent. Cancer Metastasis Rev 2000; 19: 109-20.
60. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006; 6: 583-92.
61. Hofmann M, Pflanzer R, Zoller NN, Bernd A, Kaufmann R, Thaci D, et al. Vascular endothelial growth factor C-induced lymphangiogenesis decreases tumor interstitial fluid pressure and tumor. Transl Oncol 2013; 6: 398-404.
62. Pietras K, Ostman A, Sjoquist M, Buchdunger E, Reed RK, Heldin CH, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001; 61: 2929-34.
63. Pietras K, Rubin K, Sjoblom T, Buchdunger E, Sjoquist M, Heldin CH, et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002; 62: 5476-84.
64. Lee I, Boucher Y, Jain RK. Nicotinamide can lower tumor interstitial fluid pressure: mechanistic and therapeutic implications. Cancer Res 1992; 52: 3237-40.
65. Griffon-Etienne G, Boucher Y, Brekken C, Suit HD, Jain RK. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res 1999; 59: 3776-82.
66. Taghian AG, Abi-Raad R, Assaad SI, Casty A, Ancukiewicz M, Yeh E, et al. Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications. J Clin Oncol 2005; 23: 1951-61.
67. Braunschweiger PG, Schiffer LM. Effect of dexamethasone on vascular function in RIF-1 tumors. Cancer Res 1986; 46: 3299-303.
68. Kristjansen PE, Boucher Y, Jain RK. Dexamethasone reduces the interstitial fluid pressure in a human colon adenocarcinoma xenograft. Cancer Res 1993; 53: 4764-6.
69. Toole BP, Hascall VC. Hyaluronan and tumor growth. Am J Pathol 2002; 161: 745-7.
70. Kultti A, Li X, Jiang P, Thompson CB, Frost GI, Shepard HM. Therapeutic targeting of hyaluronan in the tumor stroma. Cancers (Basel) 2012; 4: 873-903.
71. Brekken C, de Lange Davies C. Hyaluronidase reduces the interstitial fluid pressure in solid tumours in a non-linear concentration-dependent manner. Cancer Lett 1998; 131: 65-70.
72. Lokeshwar VB, Lokeshwar BL, Pham HT, Block NL. Association of elevated levels of hyaluronidase, a matrixdegrading enzyme, with prostate cancer progression. Cancer Res 1996; 56: 651-7.
73. Tamakoshi K, Kikkawa F, Maeda O, Suganuma N, Yamagata S, Yamagata T, et al. Hyaluronidase activity in gynaecological cancer tissues with different metastatic forms. Br J Cancer 1997; 75: 1807-11.
74. Pham HT, Block NL, Lokeshwar VB. Tumor-derived hyaluronidase: a diagnostic urine marker for high-grade bladder cancer. Cancer Res 1997; 57: 778-83.
75. Rubin K, Sjoquist M, Gustafsson AM, Isaksson B, Salvessen G, Reed RK. Lowering of tumoral interstitial fluid pressure by prostaglandin E(1) is paralleled by an increased uptake of (51)Cr-EDTA. Int J Cancer 2000; 86: 636-43.
76. Salnikov AV, Iversen VV, Koisti M, Sundberg C, Johansson L, Stuhr LB, et al. Lowering of tumor interstitial fluid pressure specifically augments efficacy of chemotherapy. FASEB J 2003; 17: 1756-8.
77. Leunig M, Goetz AE, Dellian M, Zetterer G, Gamarra F, Jain RK, et al. Interstitial fluid pressure in solid tumors following hyperthermia: possible correlation with therapeutic response. Cancer Res 1992; 52: 487-90.
78. Hauck ML, Coffin DO, Dodge RK, Dewhirst MW, Mitchell JB, Zalutsky MR. A local hyperthermia treatment which enhances antibody uptake in a glioma xenograft model does not affect tumour interstitial fluid pressure. Int J Hyperthermia 1997; 13: 307-16.
79. Omidi Y. Smart multifunctional theranostics: simultaneous diagnosis and therapy of cancer. Bioimpacts 2011; 1: 145-7.
80. Aljayyoussi G, Abdulkarim M, Griffiths P, Gumbleton M. Pharmaceutical nanoparticles and the mucin biopolymer barrier. Bioimpacts 2012; 2: 173-4.
81. Torosean S, Flynn B, Axelsson J, Gunn J, Samkoe KS, Hasan T, et al. Nanoparticle uptake in tumors is mediated by the interplay of vascular and collagen density with interstitial pressure. Nanomedicine 2013; 9: 151-8.
82. Wust P, Gneveckow U, Johannsen M, Bohmer D, Henkel T, Kahmann F, et al. Magnetic nanoparticles for interstitial thermotherapy--feasibility, tolerance and achieved temperatures. Int J Hyperthermia 2006; 22: 673-85.
83. Li L, ten Hagen TL, Bolkestein M, Gasselhuber A, Yatvin J, van Rhoon GC, et al. Improved intratumoral nanoparticle extravasation and penetration by mild hyperthermia. J Control Release 2013; 167: 130-7.
84. Dutz S, Kettering M, Hilger I, Muller R, Zeisberger M. Magnetic multicore nanoparticles for hyperthermia--influence of particle immobilization in tumour tissue onmagnetic properties. Nanotechnology 2011; 22: 265102.
85. Johannsen M, Thiesen B, Wust P, Jordan A. Magnetic nanoparticle hyperthermia for prostate cancer. Int J Hyperthermia 2010; 26: 790-5.
86. McGuire S, Yuan F. Improving interstitial transport of macromolecules through reduction in cell volume fraction in tumor tissues. Nanomedicine 2012; 8: 1088-95.
87. Wong C, Stylianopoulos T, Cui J, Martin J, Chauhan VP, Jiang W, et al. Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc Natl Acad Sci U S A 2011; 108: 2426-31.
88. Kim JK, Yuan H, Nie J, Yang YT, Leggas M, Potter PM, et al. High payload dual therapeutic-imaging nanocarriers for triggered tumor delivery. Small 2012; 8: 2895-903.
89. Mizrahy S, Goldsmith M, Leviatan-Ben-Arye S, Kisin-Finfer E, Redy O, Srinivasan S, et al. Tumor targeting profiling of hyaluronan-coated lipid based-nanoparticles. Nanoscale 2014; 6: 3742-52.
90. Kao HW, Lin YY, Chen CC, Chi KH, Tien DC, Hsia CC, et al. Biological characterization of cetuximab-conjugated gold nanoparticles in a tumor animal model. Nanotechnology 2014; 25: 295102.
91. Jing L, Liang X, Deng Z, Feng S, Li X, Huang M, et al. Prussian blue coated gold nanoparticles for simultaneous photoacoustic/CT bimodal imaging and photothermal ablation of cancer. Biomaterials 2014; 35: 5814-21.
92. Gutrath BS, Beckmann MF, Buchkremer A, Eckert T, Timper J, Leifert A, et al. Size-dependent multispectral photoacoustic response of solid and hollow gold nanoparticles. Nanotechnology 2012; 23: 225707.
93. Mallidi S, Larson T, Tam J, Joshi PP, Karpiouk A, Sokolov K, et al. Multiwavelength photoacoustic imaging and plasmon resonance coupling of gold nanoparticles for selective detection of cancer. Nano Lett 2009; 9: 2825-31.
94. Matthaiou EI, Barar J, Sandaltzopoulos R, Li C, Coukos G, Omidi Y. Shikonin-loaded antibody-armed nanoparticles for targeted therapy of ovarian cancer. Int J Nanomedicine 2014; 9: 1855-70.
95. Najar AG, Pashaei-Asl R, Omidi Y, Farajnia S, Nourazarian AR. EGFR antisense oligonucleotides encapsulated with nanoparticles decrease EGFR, MAPK1 and STAT5 expression in a human colon cancer cell line. Asian Pac J Cancer Prev 2013; 14: 495-8.
96. Barar J, Omidi Y. Targeted Gene Therapy of Cancer: Second Amendment toward Holistic Therapy. Bioimpacts 2013; 3: 49-51.
97. Yari Khosoushahi A, Naderi-Manesh H, Yeganeh H, Barar J, Omidi Y. Novel water-soluble polyurethane nanomicelles for cancer chemotherapy: physicochemical characterization and cellular activities. J Nanobiotechnology 2012; 10: 2.
98. Nourazarian AR, Pashaei-Asl R, Omidi Y, Najar AG. c-Src antisense complexed with PAMAM denderimes decreases of c-Src expression and EGFR-dependent downstream genes in the human HT-29 colon cancer cell line. Asian Pac J Cancer Prev 2012; 13: 2235-40.
99. Nourazarian AR, Najar AG, Farajnia S, Khosroushahi AY, Pashaei-Asl R, Omidi Y. Combined EGFR and c-Src Antisense Oligodeoxynucleotides Encapsulated with PAMAM Denderimers Inhibit HT-29 Colon Cancer Cell Proliferation. Asian Pac J Cancer Prev 2012; 13: 4751-6.
100. Barar J, Omidi Y. Translational Approaches toward Cancer Gene Therapy: Hurdles and Hopes. BioImpacts 2012; 2: 127-43.
101. Omidi Y. CNT Nanobombs for Specific Eradication of Cancer Cells: A New Concept in Cancer Theranostics. Bioimpacts 2011; 1: 199-201.
102. Majidi J, Barar J, Baradaran B, Abdolalizadeh J, Omidi Y. Target therapy of cancer: implementation of monoclonal antibodies and nanobodies. Hum Antibodies 2009; 18: 81-100.
103. Omidi Y, Kafil V, Barar J, editors. Toxicogenomics of Nonviral Cationic Gene Delivery Nanosystems. Non-Viral Gene Therapy; 2011: InTech.
104. Barar J, Hamzeiy H, Mortazavi-Tabatabaei SA, Hashemi-Aghdam SE, Omidi Y. Genomic signature and toxicogenomics comparison of polycationic gene delivery nanosystems in human alveolar epithelial A549 cells. Daru 2009; 17: 139-47.
105. Omidi Y, Barar J, Heidari HR, Ahmadian S, Yazdi HA, Akhtar S. Microarray analysis of the toxicogenomics and the genotoxic potential of a cationic lipid-based gene delivery nanosystem in human alveolar epithelial a549 cells. Toxicol Mech Methods 2008; 18: 369-78.
106. Hollins AJ, Omidi Y, Benter IF, Akhtar S. Toxicogenomics of drug delivery systems: Exploiting delivery system-induced changes in target gene expression to enhance siRNA activity. J Drug Target 2007; 15: 83-8.
107. Omidi Y, Barar J, Akhtar S. Toxicogenomics of cationic lipid-based vectors for gene therapy: impact of microarray technology. Curr Drug Deliv 2005; 2: 429-41.
108. Omidi Y, Hollins AJ, Benboubetra M, Drayton R, Benter IF, Akhtar S. Toxicogenomics of non-viral vectors for gene therapy: a microarray study of lipofectin- and oligofectamine-induced gene expression changes in human epithelial cells. J Drug Target 2003; 11: 311-23.
109. Barar J, Omidi Y. Intrinsic bio-signature of gene delivery nanocarriers may impair gene therapy goals. Bioimpacts 2013; 3: 105-9.
110. Li Y, Wang J, Wientjes MG, Au JL. Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor. Adv Drug Deliv Rev 2012; 64: 29-39.
111. Ernsting MJ, Murakami M, Roy A, Li SD. Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J Control Release 2013; 172: 782-94.
112. Swartz MA, Hubbell JA, Reddy ST. Lymphatic drainage function and its immunological implications: from dendritic cell homing to vaccine design. Semin Immunol 2008; 20: 147-56.
113. Swartz MA, Fleury ME. Interstitial flow and its effects in soft tissues. Annu Rev Biomed Eng 2007; 9: 229-56.
114. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res 2000; 60: 2497-503.
115. Fukumura D, Jain RK. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem 2007; 101: 937-49.
116. Fukumura D, Jain RK. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res 2007; 74: 72-84.
117. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62.
118. Jain RK. Normalizing tumor vasculature with antiangiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7: 987-9.
119. Boucher Y, Leunig M, Jain RK. Tumor angiogenesis and interstitial hypertension. Cancer Res 1996; 56: 4264-6